Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02156739 · ClinicalTrials.gov registry record · NA
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
A NA study of Hepatocellular Carcinoma and Metastatic Malignant Neoplasm in the Liver, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT02156739 is a NA study of Hepatocellular Carcinoma and Metastatic Malignant Neoplasm in the Liver that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02156739, a NA study of Hepatocellular Carcinoma and Metastatic Malignant Neoplasm in the Liver, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.
Conditions Studied
Interventions
- PROCEDURE Contrast-enhanced Magnetic Resonance Imaging
- DRUG Gadobutrol
- DRUG Gadoxetate Disodium
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02156739
The ClinicalTrials.gov registry entry for NCT02156739 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Contrast-enhanced Magnetic Resonance Imaging is the first listed.
NCT02156739 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02156739 about?
NCT02156739 is a clinical study titled "Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions". This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, ...
What is the current status of trial NCT02156739?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2014-10-13. Estimated completion is 2026-06-01.
What conditions does trial NCT02156739 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver, Liver and Intrahepatic Bile Duct Disorder, Primary Malignant Liver Neoplasm.
What interventions are being tested in trial NCT02156739?
The interventions under investigation include: Contrast-enhanced Magnetic Resonance Imaging (PROCEDURE), Gadobutrol (DRUG), Gadoxetate Disodium (DRUG).
Who is sponsoring clinical trial NCT02156739?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02156739 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
Explore more on PlainTrial
Hepatocellular Carcinoma
All registered trials for this condition
Metastatic Malignant Neoplasm in the Liver
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.